- $3.32bn
- $3.39bn
- $2.35bn
- 96
- 63
- 91
- 97
Annual balance sheet for Amedisys, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 81.8 | 42.7 | 40.5 | 126 | 303 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 260 | 287 | 309 | 328 | 306 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 362 | 357 | 389 | 497 | 632 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 117 | 120 | 119 | 131 | 124 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,567 | 1,857 | 1,976 | 2,060 | 2,139 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 456 | 374 | 356 | 474 | 514 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 758 | 926 | 925 | 994 | 1,004 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 809 | 931 | 1,052 | 1,067 | 1,135 |
| Total Liabilities & Shareholders' Equity | 1,567 | 1,857 | 1,976 | 2,060 | 2,139 |
| Total Common Shares Outstanding |